Media

Onxeo Implements an Equity Line Financing Including an Incentive Program with Nice & Green SA

Cash for Operations Extended to Q3 2020 Paris (France), June 15, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announces the initiation of an equity financing line through the issuance of…read more →

Onxeo Secures $7.5 Million of Non-dilutive Capital from SWK Holdings Corporation Through Sale of Rights related to Future Beleodaq® Royalties

  Transaction reinforces Company’s cash position and proceeds will be fully allocated to the advancement of Onxeo’s pipeline, including its lead product candidate, AsiDNA™   Paris (France), June 7, 2018 – 07h00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, notably against…read more →

Onxeo to Present at BIO International Convention in Boston

Paris (France), May 23, 2018 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, notably against rare or resistant forms of cancer, today announced that Judith Greciet, the Company’s Chief Executive Officer, will present at the 25th BIO International Convention. The conference is being…read more →

Onxeo Provides Business Update and Reports First Quarter 2018 Financial Information

Development of lead product candidate, AsiDNA™, for the treatment of advanced solid tumors, progressing according to plan DRIIV phase I clinical trial ongoing Interim results expected in H2 2018 Cash position of €9.2 million at March 31, 2018, sufficient to support Company’s operations until mid-2019, including through multiple key catalysts Paris (France), May 16, 2018 – 06:00 pm CEST –…read more →

Annual General Meeting of May 16, 2018

Approval of all ordinary resolutions Renewal of the terms of office of Mr. Thomas Hofstaetter Notice of a new Extraordinary General Meeting on June 19, 2018  Paris (France), May 16, 2018 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, notably against rare or…read more →

Combined General Meeting on May 16, 2018

Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced that the Onxeo shareholders are invited to attend the Company’s Combined Ordinary and Extraordinary General Meeting which will be held on Wednesday,…read more →

Publication of 2017 Registration Document

Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced the publication of the Company’s 2017 Registration Document. The 2016 Registration Document, filed with the French Market Authorities (Autorité des Marchés Financiers)…read more →

Onxeo Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA™ for Treatment of Advanced Solid Tumor

First patient has been dosed with AsiDNA™, Company’s first-in-class DNA Repair Inhibitor Study approved in France and Belgium, and conducted in three internationally-renowned clinical centers Interim results expected in second half of 2018 Paris (France), April 24, 2018 – 06:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative…read more →

Onxeo to Present Corporate Overview at the H.C. Wainwright Annual Global Life Sciences Conference

Advancing innovation towards breakthrough cancer therapies Paris, April 9, 2018 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announced that Nicolas Fellmann, CFO of Onxeo, will present and hold one-to-one meetings with investors at the…read more →

Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update

Advancement of core pipeline assets on track with key development catalysts expected in 2018 First new molecule generated from platON™, Onxeo’s proprietary development platform, to enter preclinical studies by end of 2018 Cash position of €14.3m at December 31, 2017, to support current operating plan through mid-2019 Paris, March 29, 2018 – 6:00 pm CEST -  Onxeo S.A. (Euronext Paris,…read more →

Onxeo to Present Results of Two Studies Highlighting Potential of AsiDNA™ as Anti-Cancer Treatment at 2018 AACR Annual Meeting

Paris (France), March 15th, 2018 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and resistant forms of cancer, today announced the presentation of two preclinical study abstracts highlighting AsiDNA™, the Company’s first-in-class DNA break repair inhibitor candidate, at the upcoming…read more →

Onxeo Provides Financial Update

Paris (France), March 14th, 2018 – 8:30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and resistant forms of cancer, today announced that it will record an impairment charge of about €38 million in its 2017 consolidated accounts pursuant to value tests…read more →

Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent

Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent, extending IP protection in Europe until 2031 Composition of matter patent to be granted in Europe on several products including AsiDNA™ as such until 2031, with potential extension to 2036 Onxeo’s intellectual property for DNA-targeting technologies, products and combinations now protected by 10 patent families worldwide   Paris (France), January 25,…read more →

Onxeo Provides Update on Litigation with SpeBio/SpePharm

Paris (France), January 23, 2018 – 09:30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and resistant forms of cancer, announces that it has submitted its conclusions to the Paris Court of Appeal concerning merits of the litigation…read more →